Carl Sandén

Company: Lead Biologics

Job title: Chief Scientific Officer

Seminars:

Exploring SLAMF6 as a Novel Target in Cancer Immunotherapy 11:45 am

Revealing SLAMF6 upregulation in cancer models as a new immune escape mechanism, advancing our understanding of tumour immune evasion Demonstrating SLAMF6 modulation in preclinical models and its critical role in protecting cancer cells from T cell-mediated killing Disrupting the SLAMF6 interaction in tumour models with Lead Biologics’ candidate antibody LB-116, triggering a potent anti-cancer immune…Read more

day: Conference Day One